Midodrine efficacy in orthostatic hypotension.
作者信息
Murad M Hassan, Singh Balwinder, Parsaik Ajay A
机构信息
Division of Preventive Medicine, Mayo Clinic, Rochester, NY, USA.
出版信息
J Gen Intern Med. 2014 Nov;29(11):1442-3. doi: 10.1007/s11606-014-3013-8.
Abstract
摘要
相似文献
1
Midodrine efficacy in orthostatic hypotension.米多君对体位性低血压的疗效。
J Gen Intern Med. 2014 Nov;29(11):1442-3. doi: 10.1007/s11606-014-3013-8.
2
Midodrine efficacy in orthostatic hypotension.米多君治疗直立性低血压的疗效
J Gen Intern Med. 2014 Nov;29(11):1440-1. doi: 10.1007/s11606-014-3014-7.
3
Effectiveness of droxidopa compared to midodrine in standing blood pressure and orthostatic tolerance in adults with neurogenic orthostatic hypotension: a systematic review protocol.在患有神经源性直立性低血压的成年人中，与米多君相比，屈昔多巴对站立血压和直立耐受性的有效性：一项系统评价方案
JBI Database System Rev Implement Rep. 2017 Sep;15(9):2287-2294. doi: 10.11124/JBISRIR-2016-003306.
4
Efficacy of midodrine for neurogenic orthostatic hypotension. Reply.米多君治疗神经源性直立性低血压的疗效。回复。
JAMA. 1997 Aug 6;278(5):388. doi: 10.1001/jama.1997.03550050050029.
5
Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials.米多君治疗直立性低血压：临床试验的系统评价和荟萃分析。
J Gen Intern Med. 2013 Nov;28(11):1496-503. doi: 10.1007/s11606-013-2520-3. Epub 2013 Jun 18.
6
Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease.在患有神经源性直立性低血压和帕金森病的患者中，将屈昔多巴添加到氟氢可的松或米多君中。
Clin Auton Res. 2017 Jul;27(Suppl 1):29-31. doi: 10.1007/s10286-017-0434-6. Epub 2017 Jul 3.
7
8
Trials to address efficacy of midodrine 18 years after it gains FDA approval.在米多君获得美国食品药品监督管理局（FDA）批准18年后进行的关于其疗效的试验。
JAMA. 2012 Mar 21;307(11):1124, 1127. doi: 10.1001/jama.2012.291.
9
Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study.盐酸米多君对症状性直立性低血压的临床疗效：一项4期、双盲、安慰剂对照、随机倾斜试验研究
Clin Auton Res. 2016 Aug;26(4):269-77. doi: 10.1007/s10286-016-0363-9. Epub 2016 Jul 2.
10
Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials.体位性低血压患者使用屈昔多巴和米多君的立位和卧位血压结局：随机试验的贝叶斯荟萃分析和混合治疗比较。
Ann Pharmacother. 2018 Dec;52(12):1182-1194. doi: 10.1177/1060028018786954. Epub 2018 Jul 4.
本文引用的文献
1
How to read a systematic review and meta-analysis and apply the results to patient care: users' guides to the medical literature.如何阅读系统评价和荟萃分析并将结果应用于患者护理：医学文献的用户指南。
JAMA. 2014 Jul;312(2):171-9. doi: 10.1001/jama.2014.5559.
2
How to use a subgroup analysis: users' guide to the medical literature.如何进行亚组分析：医学文献使用指南。
JAMA. 2014;311(4):405-11. doi: 10.1001/jama.2013.285063.
3
A systematic review of the pharmacological management of orthostatic hypotension.直立性低血压的药理学治疗的系统评价。
Int J Clin Pract. 2013 Jul;67(7):633-46. doi: 10.1111/ijcp.12122.
4
Content area experts as authors: helpful or harmful for systematic reviews and meta-analyses?作为作者的领域专家：对系统评价和荟萃分析是有帮助还是有危害？
BMJ. 2012 Nov 1;345:e7031. doi: 10.1136/bmj.e7031.
5
Efficacy of treatments for orthostatic hypotension: a systematic review.直立性低血压治疗效果的系统评价。
Age Ageing. 2012 Sep;41(5):587-94. doi: 10.1093/ageing/afs061. Epub 2012 May 16.
6
Trials to address efficacy of midodrine 18 years after it gains FDA approval.在米多君获得美国食品药品监督管理局（FDA）批准18年后进行的关于其疗效的试验。
JAMA. 2012 Mar 21;307(11):1124, 1127. doi: 10.1001/jama.2012.291.
7
Withdrawing FDA approval of midodrine after marketing.在米多君上市后撤回美国食品药品监督管理局的批准。
JAMA. 2011 Feb 23;305(8):781-2; author reply 782. doi: 10.1001/jama.2011.161.
Zotero 插件